LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $111K rose 208.3% year over year, behind the +306.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at +229.8% a year.
Context
- Depreciation & amortization amounted to 1.5% of revenue in FY2025.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +208.3% toward the trailing-twelve-month pace of +306.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 287K USD
- Year-over-year change
- +394.8%
- 4-year CAGR
- -20.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 287K | +394.8% |
| FY2024 | 2024-12-31 | 58K | +286.7% |
| FY2023 | 2023-12-31 | 15K | +87.5% |
| FY2022 | 2022-12-31 | 8K | -98.9% |
| FY2021 | 2021-12-31 | 734K | — |
Depreciation & Amortization vs competitors
How LENZ compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +306.7% is the 2nd highest of 11, against a peer median of +7.9%.
- Depreciation & amortization amounts to 1.7% of revenue for LENZ, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $56.96M USD | -3.2% | +16.6% | 27.3% | |
| LTM Mar 2026 | $7.48M USD | +14.8% | +34.3% | 185.3% | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $3.45M USD | +889.9% | +62.4% | 3.5% |
| FY2025 | €1.5M EUR | +152.5% | -0.1% | 5.0% | |
| LTM Mar 2026 | $1.04M USD | -17.2% | +11.5% | 0.5% | |
| LTM Mar 2026 | $541K USD | +0.2% | +22.6% | — | |
| LTM Mar 2026 | $362K USD | +306.7% | +229.8% | 1.7% | |
| LTM Mar 2026 | $350K USD | +12.5% | +92.4% | — | |
| LTM Mar 2026 | $214K USD | +28.9% | +99.2% | — | |
| LTM Mar 2026 | $44K USD | -96.8% | -36.6% | 0.0% | |
| LTM Mar 2026 | $31K USD | +3.3% | +33.6% | — | |
| Peer median (excluding LENZ) | — | +7.9% | +28.1% | 4.3% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15M | 0 | 0 | 19.09M |
| Cost of Revenue | 734K | 0 | 0 | 58K | 705K |
| Gross Profit | (734K) | 15M | 0 | (58K) | 18.38M |
| Gross Margin | — | 100.0% | — | — | 96.3% |
| Research & Development | 37.93M | 21.13M | 59.5M | 29.8M | 18.67M |
| Selling, General & Admin | 21.78M | 4.36M | 12.93M | 28.75M | 90.85M |
| Operating Expenses | 59.71M | 25.48M | 72.43M | 58.55M | 109.52M |
| Depreciation & Amortization | 734K | 8K | 15K | 58K | 287K |
| EBITDA | (70.03M) | (10.46M) | (70.13M) | (49.71M) | (81.34M) |
| EBITDA Margin | — | -69.7% | — | — | -426.1% |
| Operating Income | (60.44M) | (10.48M) | (72.43M) | (58.61M) | (91.14M) |
| Operating Margin | — | -69.9% | — | — | -477.5% |
| Interest Income | 0 | 0 | 2.19M | 8.55M | 9.76M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (10.32M) | 19K | 2.28M | 8.84M | 9.51M |
| Income Before Tax | (70.76M) | (10.46M) | (70.15M) | (49.77M) | (81.63M) |
| Pre-Tax Margin | — | -69.8% | — | — | -427.6% |
| Income Tax Expense | 0 | 347K | (179K) | 1K | 502K |
| Net Income | (70.76M) | (10.81M) | (69.97M) | (49.77M) | (82.13M) |
| Net Margin | — | -72.1% | — | — | -430.3% |
| EPS (Basic) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| EPS (Diluted) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| Weighted Avg Shares | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
| Weighted Avg Shares (Diluted) | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.